Astragalus polysaccharide composite nanoparticles for anti-colorectal cancer and preparation method thereof

By preparing astragalus polysaccharide composite nano microspheres, the antibacterial and sustained release properties of modified polyethyleneimine nano microspheres are used to load astragalus polysaccharides to inhibit liver metastasis of colorectal cancer, solving the toxic side effects and drug resistance problems of chemotherapy drugs , improves the treatment effect and the quality of life of patients.

CN118766864BActive Publication Date: 2024-11-29THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410791116.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-19
Publication Date
2024-11-29
Estimated Expiration
2044-06-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit liver metastasis of colorectal cancer, and the toxic side effects and drug resistance problems of chemotherapy drugs lead to a decrease in the quality of life of patients.

Method used

A composite nano-microsphere of Astragalus polysaccharide prepared by four-step method is used to form modified polyethyleneimine nano-microspheres through physical association using materials such as liquid paraffin, polyethyleneimine and carboxymethyl chitosan. React with chemical grafting, introduce antibacterial and sustained release properties, and load astragalus polysaccharides to improve therapeutic effects.

Benefits of technology

It significantly inhibits the proliferation and metastasis of colorectal cancer cells, reduces the formation of liver metastasis, improves the bioavailability and sustained release performance of drugs, reduces toxic and side effects, and improves the quality of life of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118766864B_ABST
    Figure CN118766864B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of medical technology, and specifically relates to a composite nano-microsphere of astragalus polysaccharide for anti-colorectal cancer and a preparation method thereof. The present invention prepares modified polyethyleneimine nano-microspheres by a two-step method, and introduces carboxymethyl chitosan and quaternary ammonium salts on the surface of modified polyethyleneimine nano-microspheres by physical association, chemical grafting and the like. Polyethyleneimine, carboxymethyl chitosan and quaternary ammonium salts synergize to show excellent antibacterial properties, and the prepared nano-microspheres also have excellent sustained-release properties by self-crosslinking of polyethyleneimine and crosslinking and winding with carboxymethyl chitosan. The modified polyethyleneimine nano-microspheres are used to load astragalus polysaccharide, which helps to inhibit symbiotic bacterial infection, improve the bioavailability of drug particles, and thus increase the therapeutic effect of astragalus polysaccharide composite nano-microspheres against colorectal cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to astragalus polysaccharide composite nano-microspheres for treating colorectal cancer and a preparation method thereof. Background Art

[0002] Colorectal cancer (CRC) is the most common digestive system malignancy in the world. Due to its high incidence and high mortality rate, it seriously affects the quality of life and prognosis of patients. At present, the treatment of colorectal cancer is mainly surgical treatment, supplemented by chemotherapy. However, once colorectal cancer patients are diagnosed, they are mostly in the late stage, often with distant metastasis, and cannot undergo surgical treatment. The liver is the most common target organ for blood metastasis of colorectal cancer, and colorectal liver metastasis is also one of the main causes of death in colorectal cancer patients. Most colorectal cancer patients have liver metastasis at the time of diagnosis, and about 15%-25% of patients can still develop liver metastasis after radical resection of the primary colorectal cancer lesion, and the vast majority of liver metastases cannot be radically resected at first. Therefore, inhibiting colorectal liver metastasis is one of the key factors to effectively reduce the mortality rate of colorectal cancer. Although current treatments such as radiotherapy, immunotherapy, and targeted therapy can inhibit its invasion and metastasis, prolong the survival time of colorectal cancer patients, and reduce mortality, the side effects of first-line anti-tumor drugs, the easy development of drug resistance, and other shortcomings can easily lead to adverse drug reactions in patients, which reduces the quality of life of patients. In recent years, taking traditional Chinese medicine as the research object, combined with commonly used radiotherapy and chemotherapy, has achieved remarkable results in the clinical treatment of colorectal cancer, especially in prolonging survival and reducing tumor recurrence and metastasis. Therefore, it has also received more and more attention and has become a new research hotspot in clinical and basic research. Due to the characteristics of traditional Chinese medicine with few toxic side effects, multiple components, multiple targets and multiple pathways, its status in anti-tumor treatment is increasing day by day. Therefore, guided by the theory of traditional Chinese medicine, clarifying the occurrence and development mechanism of colorectal cancer, and conducting research on the treatment of colorectal cancer with traditional Chinese medicine still has important practical and social significance. Traditional Chinese medicine treats colorectal cancer with a holistic approach and treats patients based on syndrome differentiation. It can effectively inhibit the growth and metastasis of colorectal cancer cells in patients and delay the progression of the disease. Traditional Chinese medicine can enhance patients' immune function, alleviate the adverse reactions caused by the disease and drug treatment, improve patients' quality of life, and prolong their life cycle.

[0003] In traditional medicine, colorectal cancer belongs to the category of "intestinal fungus", "anal lock hemorrhoids", "intestinal accumulation", and "intestinal slippage". The main pathogenesis is deficiency of vital energy and disorder of the ascending and descending of qi. The liver metastasis of colorectal cancer belongs to the category of "transmission". According to the theory of traditional Chinese medicine, "the sufficiency of vital energy is due to the undamaged qi of the spleen and stomach". The strength of spleen and stomach function is an important basis for the normal function of the human body. Spleen deficiency is the root cause of the occurrence and progression of malignant tumors in the digestive system, and "lack of vital energy and spleen deficiency" are the fundamental causes of the onset and metastasis of colorectal cancer. Therefore, the doctor Li Dongyuan focused on treating colorectal tumors with strengthening the vital energy. He believed that "internal injury to the spleen and stomach will cause all kinds of diseases", so he put forward the view of "nourishing the vital energy and eliminating it by itself", and proposed that the treatment of colorectal cancer should focus on invigorating the vital energy of the spleen and stomach. In addition, disorder of the ascending and descending of qi is the basic pathological process of the formation of colorectal cancer and the internal mechanism that causes its overall and local changes. Regulating the qi is the key to the treatment of colorectal cancer and runs through the treatment. "Suwen·Discussion on the Five Zang Organs" says: "The six bowels transmit and transform substances but do not store them, so they are full but not full." This shows that the function of the six bowels is "to pass through". The large intestine is the lowest of the six bowels, and the smoothness is to pass through and descend. Stagnation will cause distension and fullness, and the qi will be blocked and blocked. The imbalance of ascending and descending will make the essence, blood, and body fluids unable to circulate normally. The waste of food stays in the intestines, and the moisture gathers into phlegm, the blood stagnates into blood stasis, and the food rots into turbidity and poison, resulting in the accumulation of pathological products such as phlegm, blood stasis, turbidity, and poison. The accumulation stays in the weak large intestine, further aggravating the imbalance of qi movement, and ultimately leading to the occurrence and metastasis of colorectal cancer. At present, the clinical application of traditional Chinese medicine to treat colorectal cancer and its related complications is often based on the principles of "supporting the positive energy", "supporting the positive energy and eliminating the evil", "tonifying the middle and replenishing the qi", and "supporting the positive energy and consolidating the foundation", and has achieved good results.

[0004] As a tonic Chinese herbal medicine, Astragalus has the effects of "tonifying the middle and replenishing qi" and "strengthening the body". Modern pharmacological studies have found that Astragalus has a good effect on colorectal cancer. It has been widely used as a common medicine for the treatment of diseases. It can enhance the immunity of patients with colorectal cancer and improve the survival rate and quality of life of patients. Astragalus polysaccharides (APS), as the main active ingredient in Astragalus, play an important role in tumor immunoregulation, apoptosis, inflammatory response, and reversal of tumor resistance. In addition, a number of basic experimental studies have shown that Astragalus polysaccharides can inhibit the proliferation and metastasis of colorectal cancer cells, lung cancer cells and other tumors. Chemotherapy is the main means of clinical non-surgical treatment of colorectal cancer, among which 5-fluorouracil (5-FU) is a commonly used and effective chemotherapy drug for the treatment of colorectal cancer. The emergence of tumor resistance has greatly reduced the effect of chemotherapy. In addition to significantly inhibiting the proliferation, migration and invasion of colorectal cancer cells, Astragalus polysaccharides also have a good effect on reducing the chemotherapy drug resistance of colorectal cancer cells. Clinical evidence shows that the effect of astragalus polysaccharide combined with chemotherapy drugs in the treatment of colorectal cancer is more significant than that of chemotherapy alone, which can improve the effective rate of treatment, reduce toxic and side effects, improve the function of the immune system, improve the quality of life, and prolong the survival period. In addition, astragalus polysaccharide can not only inhibit the growth of subcutaneous tumors in mice, but also regulate autophagy through the PI3K / Akt / mTOR signaling pathway to inhibit the proliferation and migration of colorectal cells. Therefore, this application believes that astragalus polysaccharide may inhibit the liver metastasis of colorectal cancer in mice in the application of in vitro experiments while preventing the occurrence of inflammatory response in mice.

[0005] The occurrence of colorectal cancer liver metastasis is a multi-step process. First, the adhesion between colorectal cancer cells is reduced, which improves the motility of tumor cells and allows them to leave the original site. They also invade the lymphatic system and portal vein system to reach the liver by degrading the basement membrane and extracellular matrix; they induce the formation of tumor microangiogenesis, escape the attack of the body's immune system, and eventually form liver metastases. Epithelial-mesenchymal transition (EMT) is one of the most critical factors in tumor invasion and metastasis, and plays a vital role in the occurrence, development, invasion and metastasis of colorectal cancer. When tumor cells undergo EMT, the expression of intercellular adhesion molecules and vimentin will change, the expression of tumor epithelial marker E-cadherin will decrease, and the expression of mesenchymal markers N-cadherin and Vimentin will increase, reducing the adhesion between cells, resulting in increased invasion and infiltration of tumor cells, thereby causing distant metastasis of tumor cells. The occurrence and development of CRC is also closely related to the regulation of the body's immune system. Inflammatory factors also play an important role in the differentiation, maturation, proliferation, activation, immunoregulation and mediation of inflammatory responses of immune cells, and participate in a variety of pathological and physiological reactions. In addition, inflammatory factors can play an important role in the occurrence and development of tumors by acting on the EMT process, promoting or inhibiting the growth and metastasis of cancer. The process of tumor EMT can be induced or regulated by a variety of growth and differentiation factors, mainly including transforming growth factor β (TGF-β). TGF-β can induce the occurrence of EMT, which in turn leads to the invasion of tumor cells. The specific action process is that the TGF-β signaling pathway binds to the TGF-β type II receptor (TGF-βRⅡ) through the TGF-β ligand, and then activates the recruitment of type I receptor (TGF-βRⅠ) and binds to it to form a trimer to activate TGF-βRⅠ. The activated type I receptor further binds to the downstream transcription factor Smads, recruits and phosphorylates Smad2 and Smad3 proteins, forms a trimeric Smad complex that enters the cell nucleus and participates in the regulation of cell junction proteins, which reduces the expression of epithelial cell marker E-cadherin and increases the expression of mesenchymal cell markers N-cadherin and vimentin, ultimately enabling tumor cells to acquire the ability to metastasize to distant sites. Currently, inhibiting tumor cell migration and invasion by regulating the EMT mediated by the TGF-β / Smad pathway has become a highly promising strategy for preventing and treating tumor metastasis.

[0006] Currently, many studies have shown that astragalus polysaccharides can regulate the TGF-β / Smad pathway to treat a number of diseases. For example, astragalus polysaccharides intervene in diseases such as liver fibrosis, kidney fibrosis, and liver cancer by regulating TGF-β / Smad. However, there has been no relevant research on whether astragalus polysaccharides can regulate the TGF-β / Smad pathway to inhibit the occurrence of EMT in colorectal cancer.

[0007] In addition, colorectal cancer is a multi-stage disease caused by multiple factors such as genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle. Studies have shown that the intestinal flora is an important player in the development of colorectal cancer. Disturbance of intestinal flora homeostasis can promote the occurrence and development of colorectal cancer by inducing inflammation, regulating host defense, oxidative stress and changing bacterial metabolites. Since the translocation of colonic commensal bacteria is closely related to the development of colorectal cancer, colorectal cancer tissues and adjacent mucosa often suffer from obvious commensal bacterial infections, which affects the treatment effect of colorectal cancer. Summary of the invention

[0008] The purpose of the present invention is to address the deficiencies of the prior art and provide an astragalus polysaccharide composite nano-microsphere for anti-colorectal cancer and a preparation method thereof.

[0009] The technical solution adopted by the present invention to achieve the above-mentioned purpose is:

[0010] A method for preparing astragalus polysaccharide composite nanoparticles for anti-colorectal cancer comprises the following steps:

[0011] S1. Under stirring conditions, liquid paraffin and Span 80 are mixed evenly, and a polyethyleneimine aqueous solution is added dropwise within 20-40 minutes, and the reaction is completed for 0.5-1.5 hours. Then, a glutaraldehyde aqueous solution is added dropwise within 1-3 hours, and the temperature is raised to 40-60° C., and the reaction is continued for 8-12 hours. The mixture is cooled to room temperature, and the mixture is centrifuged, washed, and dried to obtain polyethyleneimine nanoparticles;

[0012] S2. Dispersing the polyethyleneimine nanoparticles obtained in step S1 in ethanol under stirring, adding epichlorohydrin dropwise, heating to 55-65° C., reacting for 3-7 hours, then sequentially adding carboxymethyl chitosan aqueous solution and N,N-diisopropylethylamine, then heating to 75-90° C., continuing to react for 7-10 hours, cooling to room temperature, centrifuging, washing, and drying to obtain modified polyethyleneimine nanoparticles;

[0013] S3, under stirring conditions, dispersing astragalus polysaccharide in a phosphate buffer solution, adding the modified polyethyleneimine nanoparticles obtained in step S2, reacting at room temperature for 20-30 hours, centrifuging, washing, and drying to obtain modified polyethyleneimine nanoparticles loaded with astragalus polysaccharide;

[0014] S4. Under stirring conditions, the modified polyethyleneimine nanoparticles loaded with astragalus polysaccharide are dispersed in a phosphate buffer solution, and enteric materials and emulsifiers are added in sequence. The mixture is stirred at room temperature for 20-30 hours, and the astragalus polysaccharide composite nanoparticles are obtained after centrifugation, washing and drying.

[0015] In order to obtain astragalus polysaccharide composite nano-microspheres and improve the antibacterial performance and sustained-release performance of the nano-microspheres, the volume ratio of liquid paraffin, Span 80, polyethyleneimine aqueous solution, and glutaraldehyde aqueous solution in step S1 is 10-14:10-15:4:3-5, the mass fraction of polyethyleneimine in the polyethyleneimine aqueous solution is 10-30%, and the mass fraction of glutaraldehyde in the glutaraldehyde aqueous solution is 3-5%; the mass ratio of polyethyleneimine nano-microspheres, epichlorohydrin, carboxymethyl chitosan aqueous solution, and N,N-diisopropylethylamine in step S2 is 1:0.15-0.25:10-15:0.25-0.35, the amount of polyethyleneimine nano-microspheres added to the ethanol is 60-90 mg / mL, and the mass fraction of carboxymethyl chitosan is 1:0.15-0.25:10-15:0.25-0.35. The mass fraction of carboxymethyl chitosan in the aqueous solution is 3-5%, and the dripping speed of epichlorohydrin is 4-6 μL / s; the amount of astragalus polysaccharide added to the phosphate buffer solution in step S3 is 0.4-0.6 mg / mL, and the mass ratio of astragalus polysaccharide to modified polyethyleneimine nanomicrospheres is 1:2-4; the mass ratio of modified polyethyleneimine nanomicrospheres loaded with astragalus polysaccharide, enteric material, and emulsifier in step S4 is 10:15-25:0.7-0.8, the amount of modified polyethyleneimine nanomicrospheres loaded with astragalus polysaccharide added to the phosphate buffer solution is 50-70 mg / mL, and the enteric material consists of acrylic resin II and acrylic resin III in a mass ratio of 1:2-3; the emulsifier is polyvinyl alcohol.

[0016] The present invention also provides astragalus polysaccharide composite nano-microspheres for preventing colorectal cancer, which are prepared by the above method.

[0017] The present invention has the following beneficial effects:

[0018] The invention utilizes a four-step method to prepare astragalus polysaccharide composite nano-microspheres. Firstly, liquid paraffin and polyethyleneimine are mixed to prepare a polyethyleneimine-liquid paraffin emulsification system, and glutaraldehyde is used as a cross-linking agent to form polyethyleneimine nano-microspheres through cross-linking. Then, active amino groups on the surfaces of the polyethyleneimine nano-microspheres react with epichlorohydrin to produce an epoxy compound ring-opening reaction, and further react with carboxymethyl chitosan and N,N-diisopropylethylamine to obtain modified polyethyleneimine nano-microspheres. Then, the modified polyethyleneimine nano-microspheres are used as carriers to load astragalus polysaccharide. Finally, the modified polyethyleneimine nano-microspheres loaded with astragalus polysaccharide are mixed with an enteric material and an emulsifier to prepare astragalus polysaccharide composite nano-microspheres.

[0019] The present invention utilizes physical association, chemical grafting and other effects to introduce carboxymethyl chitosan and quaternary ammonium salt on the surface of modified polyethyleneimine nano-microspheres, polyethyleneimine and carboxymethyl chitosan and quaternary ammonium salt synergistically enhance the effect, showing excellent antibacterial properties, and through polyethyleneimine self-crosslinking, supplemented by carboxymethyl chitosan crosslinking winding, the prepared modified polyethyleneimine nano-microspheres also have excellent sustained-release properties. The modified polyethyleneimine nano-microspheres are used to load astragalus polysaccharide, which helps to inhibit symbiotic bacteria infection, improve the bioavailability of drug particles, and thus increase the therapeutic effect of astragalus polysaccharide composite nano-microspheres against colorectal cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 To test the antibacterial properties of modified polyethyleneimine nanoparticles against Escherichia coli;

[0021] Figure 2 To test the in vitro sustained release performance of Astragalus polysaccharide composite nanoparticles;

[0022] Figure 3 The weight change trend of mice in each group;

[0023] Figure 4 This is a gross observation of mouse liver metastasis;

[0024] Figure 5 To detect the imaging results of metastatic lesions using in vivo imaging;

[0025] Figure 6 Mouse liver tissue pathological staining (200x);

[0026] Figure 7 The expression of TGF-β / Smad signaling pathway proteins and EMT-related proteins in mouse liver metastases;

[0027] Figure 8 The expression of inflammatory factors such as TNF-α, IL-1β, and IL-6 in mouse serum;

[0028] Fig. 9 The expression of E-Cadherin, N-Cadherin and Vimentin mRNA in mouse liver metastases. DETAILED DESCRIPTION

[0029] The following will be combined with the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0030] In the technical scheme of the present invention, the raw materials and reagents used in the following embodiments, comparative examples and related experiments are all common commercially available products, and the related detection methods involved are all conventional technical detections, including carboxymethyl chitosan (MW = 8.5kDa, deacetylation degree = 90%, carboxymethylation degree = 85%), pharmaceutical grade; astragalus polysaccharide CAS No. 89250-26-0; liquid paraffin (active ingredient content 99%), pharmaceutical grade; epichlorohydrin CAS No. 106-89-8; polyethyleneimine (MW = 5kDa, purity 99%), pharmaceutical grade; N, N-diisopropylethylamine CAS No. 7087-68-5.

[0031] Example 1

[0032] A method for preparing astragalus polysaccharide composite nanoparticles for anti-colorectal cancer comprises the following steps:

[0033] S1. Under stirring at 180 rpm, liquid paraffin and Span 80 were mixed evenly, polyethyleneimine aqueous solution was added dropwise within 30 minutes, the reaction was continued for 1 hour, and glutaraldehyde aqueous solution was added dropwise within 2 hours, the temperature was raised to 50°C, the reaction was continued for 10 hours, the mixture was cooled to room temperature, and the mixture was centrifuged at 5000 rpm for 5 minutes, the supernatant was removed, and the precipitate was washed with ethanol and water in turn, and freeze-dried to obtain polyethyleneimine nanospheres; wherein the volume ratio of liquid paraffin, Span 80, polyethyleneimine aqueous solution, and glutaraldehyde aqueous solution was 12:12:4:4; the mass fraction of polyethyleneimine in the polyethyleneimine aqueous solution was 20%, and the mass fraction of glutaraldehyde in the glutaraldehyde aqueous solution was 4%;

[0034] S2. Disperse the polyethyleneimine nanospheres obtained in step S1 in ethanol under stirring at 180 rpm, add epichlorohydrin dropwise, heat to 60°C, react for 5 h, then add carboxymethyl chitosan aqueous solution and N,N-diisopropylethylamine in sequence, heat to 85°C, continue to react for 8 h, cool to room temperature, centrifuge at 5000 rpm for 5 min, remove the supernatant, wash the precipitate with ethanol and water in sequence, and freeze-dry to obtain modified polyethyleneimine nanospheres; wherein the mass ratio of polyethyleneimine nanospheres, epichlorohydrin, carboxymethyl chitosan aqueous solution, and N,N-diisopropylethylamine is 1:0.2:12:0.3, the amount of polyethyleneimine nanospheres added in ethanol is 80 mg / mL, the mass fraction of carboxymethyl chitosan in the carboxymethyl chitosan aqueous solution is 4%, and the dripping speed of epichlorohydrin is 5 μL / s;

[0035] S3, under stirring at 180 rpm, dispersing astragalus polysaccharide in a phosphate buffer solution (sterile, pH 7.4), adding the modified polyethyleneimine nanospheres obtained in step S2, reacting at room temperature for 24 h, centrifuging at 5000 rpm for 5 min, removing the supernatant, washing the precipitate with a phosphate buffer solution, and freeze-drying to obtain modified polyethyleneimine nanospheres loaded with astragalus polysaccharide; wherein the amount of astragalus polysaccharide added to the phosphate buffer solution is 0.5 mg / mL, and the mass ratio of astragalus polysaccharide to modified polyethyleneimine nanospheres is 1:3;

[0036] S4. Under stirring at 180 rpm, the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide are dispersed in a phosphate buffer solution (sterile, pH 7.4), and enteric materials and emulsifiers are added in sequence. The mixture is stirred at room temperature for 24 h, centrifuged at 5000 rpm for 5 min, the supernatant is removed, and the precipitate is washed with a phosphate buffer solution and freeze-dried to obtain astragalus polysaccharide composite nanospheres. The average particle size of the astragalus polysaccharide composite nanospheres is 81 nm. The mass ratio of the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide, the enteric material and the emulsifier is 10:20:0.75, and the amount of the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide in the phosphate buffer solution is 60 mg / mL. The enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2.5. The emulsifier is polyvinyl alcohol.

[0037] Example 2

[0038] A method for preparing astragalus polysaccharide composite nanoparticles for anti-colorectal cancer comprises the following steps:

[0039] S1. Under stirring at 180 rpm, liquid paraffin and Span 80 were mixed evenly, polyethyleneimine aqueous solution was added dropwise within 20 min, the reaction was continued for 1.5 h, glutaraldehyde aqueous solution was added dropwise within 1 h, the temperature was raised to 50° C., the reaction was continued for 11 h, the mixture was cooled to room temperature, centrifuged at 5000 rpm for 5 min, the supernatant was removed, and the precipitate was washed with ethanol and water in turn, and freeze-dried to obtain polyethyleneimine nanospheres; wherein the volume ratio of liquid paraffin, Span 80, polyethyleneimine aqueous solution, and glutaraldehyde aqueous solution was 10:10:4:3; the mass fraction of polyethyleneimine in the polyethyleneimine aqueous solution was 15%, and the mass fraction of glutaraldehyde in the glutaraldehyde aqueous solution was 3%;

[0040] S2. Disperse the polyethyleneimine nanospheres obtained in step S1 in ethanol under stirring at 180 rpm, add epichlorohydrin dropwise, heat to 55°C, react for 7 h, then add carboxymethyl chitosan aqueous solution and N,N-diisopropylethylamine in sequence, heat to 75°C, continue to react for 10 h, cool to room temperature, centrifuge at 5000 rpm for 5 min, remove the supernatant, wash the precipitate with ethanol and water in sequence, and freeze-dry to obtain modified polyethyleneimine nanospheres; wherein the mass ratio of polyethyleneimine nanospheres, epichlorohydrin, carboxymethyl chitosan aqueous solution, and N,N-diisopropylethylamine is 1:0.15:10:0.25, the amount of polyethyleneimine nanospheres added in ethanol is 70 mg / mL, the mass fraction of carboxymethyl chitosan in the carboxymethyl chitosan aqueous solution is 3%, and the dripping speed of epichlorohydrin is 5 μL / s;

[0041] S3, under stirring at 180 rpm, dispersing astragalus polysaccharide in a phosphate buffer solution (sterile, pH 7.4), adding the modified polyethyleneimine nanospheres obtained in step S2, reacting at room temperature for 24 h, centrifuging at 5000 rpm for 5 min, removing the supernatant, washing the precipitate with a phosphate buffer solution, and freeze-drying to obtain modified polyethyleneimine nanospheres loaded with astragalus polysaccharide; wherein the amount of astragalus polysaccharide added to the phosphate buffer solution is 0.5 mg / mL, and the mass ratio of astragalus polysaccharide to modified polyethyleneimine nanospheres is 1:2;

[0042] S4. Under stirring at 180 rpm, the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide are dispersed in a phosphate buffer solution (sterile, pH 7.4), and enteric material and emulsifier are added in sequence. The mixture is stirred at room temperature for 24 h, centrifuged at 5000 rpm for 5 min, the supernatant is removed, and the precipitate is washed with a phosphate buffer solution and freeze-dried to obtain astragalus polysaccharide composite nanospheres. The average particle size of the astragalus polysaccharide composite nanospheres is 76 nm. The mass ratio of the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide, the enteric material and the emulsifier is 10:15:0.7, and the amount of the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide in the phosphate buffer solution is 50 mg / mL. The enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2.5. The emulsifier is polyvinyl alcohol.

[0043] Example 3

[0044] A method for preparing astragalus polysaccharide composite nanoparticles for anti-colorectal cancer comprises the following steps:

[0045] S1. Under stirring at 180 rpm, liquid paraffin and Span 80 were mixed evenly, polyethyleneimine aqueous solution was added dropwise within 40 min, the reaction was carried out for 0.5 h, and glutaraldehyde aqueous solution was added dropwise within 3 h, the temperature was raised to 50° C., the reaction was continued for 9 h, the mixture was cooled to room temperature, and the mixture was centrifuged at 5000 rpm for 5 min, the supernatant was removed, and the precipitate was washed with ethanol and water in turn, and freeze-dried to obtain polyethyleneimine nanospheres; wherein the volume ratio of liquid paraffin, Span 80, polyethyleneimine aqueous solution, and glutaraldehyde aqueous solution was 14:14:4:5; the mass fraction of polyethyleneimine in the polyethyleneimine aqueous solution was 25%, and the mass fraction of glutaraldehyde in the glutaraldehyde aqueous solution was 5%;

[0046] S2. Disperse the polyethyleneimine nanospheres obtained in step S1 in ethanol under stirring at 180 rpm, add epichlorohydrin dropwise, heat to 65°C, react for 3 h, then add carboxymethyl chitosan aqueous solution and N,N-diisopropylethylamine in sequence, heat to 90°C, continue to react for 7 h, cool to room temperature, centrifuge at 5000 rpm for 5 min, remove the supernatant, wash the precipitate with ethanol and water in sequence, and freeze-dry to obtain modified polyethyleneimine nanospheres; wherein the mass ratio of polyethyleneimine nanospheres, epichlorohydrin, carboxymethyl chitosan aqueous solution, and N,N-diisopropylethylamine is 1:0.25:14:0.35, the amount of polyethyleneimine nanospheres added in ethanol is 90 mg / mL, the mass fraction of carboxymethyl chitosan in the carboxymethyl chitosan aqueous solution is 5%, and the dripping speed of epichlorohydrin is 5 μL / s;

[0047] S3, under stirring at 180 rpm, dispersing astragalus polysaccharide in a phosphate buffer solution (sterile, pH 7.4), adding the modified polyethyleneimine nanospheres obtained in step S2, reacting at room temperature for 24 h, centrifuging at 5000 rpm for 5 min, removing the supernatant, washing the precipitate with a phosphate buffer solution, and freeze-drying to obtain modified polyethyleneimine nanospheres loaded with astragalus polysaccharide; wherein the amount of astragalus polysaccharide added to the phosphate buffer solution is 0.5 mg / mL, and the mass ratio of astragalus polysaccharide to modified polyethyleneimine nanospheres is 1:4;

[0048] S4. Under stirring at 180 rpm, the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide are dispersed in a phosphate buffer solution (sterile, pH 7.4), and enteric material and emulsifier are added in sequence. The mixture is stirred at room temperature for 24 h, centrifuged at 5000 rpm for 5 min, the supernatant is removed, and the precipitate is washed with a phosphate buffer solution and freeze-dried to obtain astragalus polysaccharide composite nanospheres. The average particle size of the astragalus polysaccharide composite nanospheres is 85 nm. The mass ratio of the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide, the enteric material and the emulsifier is 10:25:0.8, and the amount of the modified polyethyleneimine nanospheres loaded with astragalus polysaccharide in the phosphate buffer solution is 70 mg / mL. The enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2.5. The emulsifier is polyvinyl alcohol.

[0049] Antibacterial property test of modified polyethyleneimine nanoparticles

[0050] The antibacterial properties of the modified polyethyleneimine nanoparticles prepared in Examples 1-3 were tested. The polyethyleneimine nanoparticles prepared in Example 1 were used as the control group, and the nanoparticles of different concentrations (0 μg / mL, 50 μg / mL, 100 μg / mL, 150 μg / mL, 250 μg / mL) were mixed with 100 μL, 2×10 6 The E. coli solution containing CFU / mL was mixed evenly, incubated at 37℃ and 42℃ for 2h at 110rpm, taken out, diluted, and plated. The results were as follows: Figure 1 As shown, with the increase of the concentration of modified polyethyleneimine nanoparticles, the survival rate of Escherichia coli gradually decreased. At different concentrations, the antibacterial properties of the modified polyethyleneimine nanoparticles prepared in Examples 1-3 against Escherichia coli were significantly better than those of the control group. When the concentration of the nanoparticles was 250 μg / mL, the antibacterial rates of the modified polyethyleneimine nanoparticles prepared in Examples 1-3 against Escherichia coli reached more than 99%, showing excellent antibacterial properties.

[0051] Sustained release performance test of astragalus polysaccharide composite nanoparticles

[0052] The astragalus polysaccharide composite nanoparticles prepared in Examples 1-3 were dispersed in a phosphate buffer solution to prepare a 1 mg / mL solution, and released in artificial intestinal fluid. The astragalus polysaccharide content in the released solution was determined by the phenol-sulfuric acid method on days 1, 2, 3, 4, 5, 6, and 7. The in vitro release curve of the composite nanoparticles is shown in FIG. Figure 2As shown in the figure, in the early stage of sustained release, the cumulative release rate of the astragalus polysaccharide composite nanospheres prepared in Example 2 is relatively high. In the middle stage of sustained release, the cumulative release rate of the astragalus polysaccharide composite nanospheres prepared in Example 3 is relatively high. In the late stage of sustained release, the cumulative release rate of the astragalus polysaccharide composite nanospheres prepared in Example 1 is relatively high. On the 7th day of sustained release, the cumulative release rates of the astragalus polysaccharide composite nanospheres prepared in Examples 1-3 are all above 85%. Among them, the cumulative release rate of the astragalus polysaccharide composite nanospheres prepared in Example 1 is the highest, reaching 90%, showing excellent sustained release performance, which helps to improve the bioavailability of drug particles and enhance the therapeutic effect.

[0053] Cell and animal experiments of astragalus polysaccharide composite nanospheres

[0054] Materials and methods

[0055] 1 Experimental materials

[0056] 1.1 Experimental animals

[0057] 40 SPF-grade male C57B6L mice, weighing 16.41±0.70 g, were provided by Huaxing Animal Farm in Huiji District, Zhengzhou (License number: SCXK(Yu)2020-0002).

[0058] 1.2 Experimental cells

[0059] Mouse colorectal cancer green fluorescence MC-38 cells were purchased from Hebei Beina Biotechnology Co., Ltd., with the number 353445.

[0060] 1.3 Experimental reagents

[0061] RPMI-1640 medium (Biosharp, PM150110); PBS buffer (Procell, PB180329), FBS fetal bovine serum (CELLMAX, SA201.02); trypsin (Biosharp, T1350); RIPA tissue / cell lysis buffer (EpiZyme, PC101); protease inhibitor (EpiZyme, GRF101); phosphatase inhibitor (EpiZyme, GRF102); Marker (EpiZyme, WJ103); BCA protein quantification kit (EpiZyme ZJ101); DMSO (Solarbio, D8370); rabbit anti-GAPDH (EpiZyme, AP0063); goat anti-rabbit IgG (EpiZyme, AP0063); goat anti-mouse IgG (EpiZyme, LF101); 5× Loading buffer (EpiZyme, LT101S); 10× electrophoresis buffer (EpiZyme, PS105S); 10× transfer buffer (EpiZyme, PS109S); skim milk powder (EpiZyme, PS112); ECL luminescent solution (EpiZyme, SQ201); 10× TBST (EpiZyme, PS103S); PVDF membrane (Immonilon-PSQ, ISEQ00010); methanol (Hengxing, 32058); Rabbit Anti-Vimentin antibody (bs-20412R) 50; Mouse Anti-E-cadherin antibody (bsm-33222M) 48; Rabbit Anti-N-cadherin antibody (bsm-52223R) 52; DMSO (Solarbio, D8370); reverse transcription kit (novoprotein, E047-01B); qPCR kit (novoprotein E096-01A) total RNA extraction reagent (Shanghai Yazyme YY101); HE staining kit (Beijing Solarbio Technology Co., Ltd., G1120).

[0062] 1.4 Experimental drugs

[0063] 5-Fluorouracil (Tianjin Jinyao Pharmaceutical Co., Ltd., national medicine standard number H12020959, specification: 25 mg), astragalus polysaccharide composite nanospheres prepared in Example 1.

[0064] 1.5 Experimental Instruments

[0065] The instruments used in the experiment are detailed in Table 1.

[0066] Table 1 Instruments used in the experiment

[0067]

[0068] 2 Experimental methods

[0069] 2.1 Recovery, culture, medium replacement, subculturing, and cryopreservation of fluorescent MC-38 cells

[0070] Before each cell operation, the ultraviolet light of the cell experiment clean bench must be turned on to disinfect the bench for 30 minutes, and the working area must be wiped with an alcohol cotton ball dipped in 75% alcohol.

[0071] 2.1.1 Recovery of MC-38 cells

[0072] Open the constant temperature water bath and adjust the water temperature to 37°C. Use long tweezers to put 1mL of fluorescent MC-38 cells in the liquid nitrogen tank into the constant temperature water bath for thawing. After the cells are completely dissolved, they are disinfected with alcohol and placed on the clean bench. Pipette the cell suspension into a 10mL centrifuge tube, add 5mL of complete culture medium (complete culture medium is prepared according to RPMI-1640 basal culture medium: FBS, with a ratio of 9:1), mix well and place in a low-speed centrifuge at 1000r / min. After centrifugation for 5min, discard the supernatant, add 3mL of complete culture medium, blow and mix well, use a pipette to transfer the cell suspension to a 25mL culture dish, mark with a marker, and place in a 5% CO2, 37°C incubator.

[0073] 2.1.2 Medium replacement of MC-38 cells

[0074] The MC-38 cells were taken out from the 5% CO2, 37°C incubator, and the cell morphology and growth status were observed using an inverted phase contrast microscope to check for contamination. The cell culture dish was disinfected and wiped with an alcohol lamp and placed on a clean bench. The waste liquid in the culture dish was poured out, and 2 mL of PBS buffer was used to wash the cells. After repeating this process twice, 5 mL of complete culture medium was added, and the culture dish was finally placed in a 5% CO2, 37°C constant temperature incubator.

[0075] 2.1.3 MC-38 cell passaging

[0076] The cells were taken out from the 5% CO2, 37°C constant temperature incubator, and the cell state and growth status were observed under an inverted phase contrast microscope. After the cell fusion reached 80%-90%, the spent culture medium in the cell culture dish was poured out, and the culture dish was washed twice with 2mL PBS buffer, 1mL trypsin was added, and the cells were placed in a 5% CO2, 37°C incubator for digestion for 2.5min. After the cells were digested, 2mL complete culture medium was added to terminate the digestion. The cells were gently blown with a pipette and the cell suspension was transferred to a 10mL centrifuge tube. After centrifugation at 1000r / min for 5min, the supernatant was discarded, fresh complete culture medium was added again, and after blowing 120 times to resuspend, the cells were transferred to a new cell culture dish for expansion culture. The subculture ratio was 1:2. Finally, the culture dish was placed in a 5% CO2, 37°C incubator.

[0077] 2.1.4 MC-38 cell cryopreservation

[0078] First, prepare the cell freezing solution according to the ratio of 1640 basal culture medium and FBS:DMSO of 7:2:1. Use the MC-38 cell passaging method to discard the supernatant of the centrifuged cells, use a pipette to aspirate 1 mL of cell freezing solution, blow and resuspend the cells, and transfer them into cell freezing tubes. Mark them with a marker pen, put them into a programmed freezing box and freeze them in a -80℃ refrigerator overnight. On the second day, put the cryotubes into liquid nitrogen for long-term storage.

[0079] 2.2 Mouse husbandry

[0080] Mouse breeding: C57B6L mice were raised in the Central Laboratory Animal Center of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, and were used in the experiment after one week of adaptive feeding.

[0081] 2.3 Preparation of mouse liver metastasis model

[0082] A mouse colorectal cancer liver metastasis model was prepared by injecting mouse colorectal cancer cells (fluorescent MC-38 mouse colorectal cancer cells) into the spleen of C57B6L mice. The mice were anesthetized by intraperitoneal injection of 5% sodium pentobarbital at a dosage of 0.1 mL / 10 g. After the mice were thoroughly anesthetized, the mouse spleen was located on the body surface, and the mouse hair around the location point was removed with a depilatory cream. The mouse limbs were fixed on a hard board, and the skin around the spleen location point was disinfected with alcohol cotton balls and iodine tincture. A 0.5-1 mm oblique incision was made under the ribs in the left upper abdomen. The abdominal cavity was opened layer by layer to find the spleen. The spleen was lifted out of the abdominal cavity using ophthalmic forceps to clamp the lower pole of the spleen and expose the spleen outside the abdominal cavity. 2×10 7MC-38 tumor cells were slowly injected into the spleen with a volume of 0.1 mL of cell suspension (the direction of the needle was parallel to the spleen and slightly tilted upward, and the needle was inserted about 3 mm). After the injection, the spleen injection point was compressed for 5 minutes to prevent spleen bleeding and tumor cell extravasation. The spleen was slowly returned to the abdominal cavity, and the abdominal cavity was sutured layer by layer. Finally, iodine was used to disinfect the sutured site. After the model was established, the mice were returned to the cage, and their general conditions such as diet, spirit, and activity were closely monitored.

[0083] 2.4 Grouping and Dosing of Mice

[0084] On the 7th day after surgery, the in vivo imaging device was used to detect whether the mouse colorectal cancer liver metastasis model was successfully prepared. The mice with successful modeling were randomly divided into model control group (Control), low-dose astragalus polysaccharide group (APS-L), medium-dose astragalus polysaccharide group (APS-M), high-dose astragalus polysaccharide group (APS-H), and 5-fluorouracil group (5-FU), with 8 mice in each group. The model control group was given 20 mL / kg.d of normal saline, the low-dose astragalus polysaccharide group was given 50 mg / kg.d of astragalus polysaccharide composite nanospheres for injection, the medium-dose astragalus polysaccharide group was given 100 mg / kg.d of astragalus polysaccharide composite nanospheres for injection, the high-dose astragalus polysaccharide group was given 250 mg / kg.d of astragalus polysaccharide composite nanospheres for injection, and the 5-fluorouracil group was given 10 mg / kg.d of fluorouracil for injection, and the drugs were administered by intraperitoneal injection for 21 consecutive days.

[0085] 2.5 Observation of general condition of mice

[0086] During the daily administration period, the general condition of the mice was observed, including spirit, diet, activity, hair, feces and wound conditions. The weight of the mice was recorded every three days, and the recording time was the weight of the mice before administration and before anesthesia for sampling.

[0087] 2.6 Mouse sampling

[0088] After the last administration, the mice were anesthetized by intraperitoneal injection of 5% sodium pentobarbital at a dosage of 0.1 mL / 10 g. After the mice were thoroughly anesthetized, the limbs of the mice were fixed on a board. The chest cavity of the mice was opened, and blood was collected from the heart using an anticoagulation blood collection tube, with a blood volume of about 0.5-1 mL. The whole blood was allowed to stand at room temperature for 2 hours, centrifuged at 3000 r / min for 30 minutes, and the serum was transferred into a new EP tube with a pipette and stored in a -80°C refrigerator. The mice were killed by dislocating the neck, and the liver tissue of the mice was taken out. The liver was divided into 3 equal parts, one part was fixed with 4% paraformaldehyde for pathological tissue examination, one part was added with RNA preservation solution and placed in a cryopreservation tube at -80°C refrigerator for low temperature storage for PCR examination, and the last part was directly placed in a cryopreservation tube at -80°C refrigerator for protein immunoblotting examination.

[0089] 2.7 HE staining to examine pathological changes in mouse liver tissue

[0090] 2.7.1 Tissue Dehydration and Embedding

[0091] Remove the liver tissue fixed in 4% paraformaldehyde (fixation time is not less than 48h), cut the tissue into several small pieces with ophthalmic scissors, clean the small pieces with clean water and dry them with absorbent paper, put them into the tissue embedding box, and soak them in 80% ethanol for 1h, 90% ethanol for 1h, and finally 95% ethanol overnight. After overnight, take out the tissue embedding box from 95% ethanol, soak it in 100% ethanol for 60min, 100% ethanol for 60min, xylene for 60min, and xylene for 60min. Melt the paraffin and soak the embedding box in paraffin I (containing xylene) for 30min, paraffin II (containing xylene) for 30min, paraffin II (without xylene) in sequence. After the paraffin is sealed, take out the tissue from the tissue embedding box and put it into the embedding mold, make corresponding marks, and wait for it to solidify completely.

[0092] 2.7.2 Tissue sectioning, dewaxing, and staining

[0093] Place the embedded wax block in a 4℃ refrigerator for 2h, slice it on a tissue slicer with a thickness of 4um, place the sliced ​​slices on a glass slide and bake them in a 60℃ baking tray for 30min. Place the glass slide in xylene I for 2min, xylene II for 2min, 100% ethanol for 2min, 100% ethanol for 2min, 95% ethanol for 2min, 90% ethanol for 2min, 80% ethanol for 2min, 70% ethanol for 2min, and distilled water for 2min, stain the nucleus with hematoxylin for 1-2min, and rinse with tap water, differentiate with 1% hydrochloric acid alcohol for 3s, and rinse with tap water; stain the cytoplasm with eosin for 2-3min, and rinse with tap water. Stain with Ponceau fuchsin for 3-5 minutes, then dehydrate with alcohol, and place the sections in 70% ethanol for 2 minutes, 80% ethanol for 2 minutes, 90% ethanol for 2 minutes, 95% ethanol for 2 minutes, 100% ethanol I for 5 minutes, 100% ethanol II for 5 minutes, xylene I for 5 minutes, and xylene II for 5 minutes. Finally, add a drop of neutral resin to seal the sections and observe under an electron microscope.

[0094] 2.8ELISA method to detect the levels of inflammatory factors TNF-α, IL-1β, and IL-6 in mouse serum

[0095] After placing the whole blood of mice at room temperature for 30 minutes, centrifuge it in a 1000xg centrifuge for 15 minutes, and take the supernatant for detection. Set the standard wells, blank wells and sample wells respectively, add 100μL of the diluted standard to the standard wells, add 100μL of the standard & sample diluent to the blank wells, and add 100μL of the sample to be tested to the remaining wells. After the sample is added, cover the enzyme plate and incubate it in a 37℃ constant temperature incubator for 90 minutes. Shake off the liquid in the wells, add 100μL of biotin antibody working solution to each well, cover the enzyme plate, and incubate it in a 37℃ constant temperature incubator for 60 minutes. Shake off the liquid in the wells, pat dry on clean absorbent paper, add 350μL of washing solution to each well, soak for 1min, and pat dry on absorbent paper. After repeating the above washing operation 3 times, immediately add 100μL of enzyme binding working solution to each well, cover the enzyme plate, and incubate it in a 37℃ constant temperature incubator for 30 minutes. Shake off the liquid in the wells and wash the plate 5 times. After washing, 90 μL of substrate solution (TMB) was added to each blank, the enzyme plate was covered with film, and incubated in a 37°C thermostat in the dark for 15 min. After incubation, 50 μL of stop solution was added to each blank to terminate the reaction, and the optical density value (OD value) of each blank was immediately detected using an ELISA reader at a wavelength of 450 nm. The concentration of the standard was used as the horizontal axis and the OD value was used as the vertical axis to draw a standard curve and calculate the sample concentration.

[0096] 2.9 Western blot detection of the expression of TGF-β1, p-Samad2, p-Samad3, E-cadherin, N-cadherin and Vimintin proteins in mouse liver tissue

[0097] 2.9.1 Extraction of liver tissue proteins to be tested

[0098] Take out 20 mg of mouse liver tissue from a -80°C refrigerator, and cut the mouse liver tissue into several pieces with sterilized tissue scissors; put the cut liver pieces into a grinder, add 20 μL RIPA lysis solution (RIPA: PMSF = 100: 1) and grind them thoroughly for 5 minutes; let it stand for 30 minutes after grinding until the tissue is fully lysed (the above operations are all performed on ice); transfer the lysed liquid to a new centrifuge tube, centrifuge at 4°C, 12000 rpm for 5 minutes, transfer the supernatant to a new centrifuge tube and store it at -20°C.

[0099] 2.9.2 Determination of protein concentration by BCA method

[0100] 1) Add protein standards into a 96-well plate in the order of 0, 1, 2, 4, 8, 16, and 20 μL, and add PBS buffer to make the total volume 20 μL. Set up 3 replica wells for each group of samples;

[0101] 2) Add 200 μL of BCA working solution to each of the above wells and place in a 37°C constant temperature shaker for 30 min; then use an enzyme reader to measure the absorbance value at 562 nm.

[0102] 2.9.3 Western Blotting

[0103] 1) Prepare 10% SDS-PAGE gel

[0104] Table 2 Preparation of 10% separation gel (12 mL)

[0105]

[0106] Table 3 Preparation of 5% concentrated gel (6 mL)

[0107]

[0108] Prepare 10% separation gel according to the above method, add TEMED and vortex to mix evenly, use a pipette to slowly inject 5mL separation gel along the gap of the glass plate. Prepare 5% concentrated gel according to the above formula, add TEMED and mix evenly, slowly fill the remaining space along the gap of the glass plate with concentrated gel, and then insert the comb into the concentrated gel. Be careful not to have bubbles under the comb. When the concentrated gel is solidified, remove the gel caster, carefully unplug the comb, and prepare to start electrophoresis (about 30 minutes); put the gel caster into the electrophoresis tank, add enough electrophoresis solution, and then load the sample for electrophoresis. The voltage of the concentrated gel is 75V, and the voltage of the separation gel is 120V. Electrophoresis can be terminated when it reaches about 1cm from the bottom of the bromophenol blue, and the membrane is transferred.

[0109] 2) Transfer

[0110] Prepare a PVDF membrane larger than the SDS-PAGE gel surface. The PVDF membrane should be activated with methanol for 2 minutes before use. Soak the sponge and filter paper in 1x electrotransfer solution, open the transfer device clip, with the black side at the bottom, and place the sponge, three filter papers, separation gel, PVDF membrane, three filter papers, sponge in the order of placement from top to bottom (slowly place the separation gel on the filter paper, place the PVDF membrane on the gel to avoid bubbles, cover the membrane with three filter papers and remove bubbles). After placing, close the white side of the transfer device and fasten it. Put it into the transfer device, humidify the transfer solution, try to cover the wires, and connect the power supply with red to red and black to black. Transfer conditions (wet transfer): 300mA constant current transfer for half an hour. During the transfer process, place the transfer device in ice water to cool down.

[0111] Table 4 Preparation of 1x electroporation buffer

[0112]

[0113] 3) Protein and antibody reaction

[0114] Place the transferred membrane in an incubation tank filled with 1xTBST, rinse it quickly once, then add skim milk, place it on a decolorizing shaker, and block it at room temperature for 30 minutes; dilute the primary antibody according to the antibody instructions, pour out the blocking solution in the incubation tank after preparation, add the prepared primary antibody, and incubate it on a shaker at 4°C overnight (shake slowly); recover the primary antibody, rinse the membrane quickly three times with 1xTBST, then add 1xTBST, place it on a decolorizing shaker for rapid elution, 5 minutes each time, wash three times; dilute the secondary antibody with 1xTBST at a ratio of 1:5000, then add it to the incubation tank, place it on a shaker for slow shaking, and incubate it at room temperature for 30 minutes; rinse the membrane quickly three times with TBST, then add 1xTBST, place it on a decolorizing shaker for rapid elution, 5 minutes each time, wash three times.

[0115] Table 5 Preparation of 1x TBST

[0116]

[0117] Table 6 Dilution ratio of internal reference and each index antibody

[0118]

[0119] 4) Chemiluminescence: In a dark room, mix the two reagents ECLA solution and ECLB solution in equal volumes in a centrifuge tube, put a double layer of PE gloves or other transparent films on the exposure box, put the PVDF membrane with the protein side facing up between the two layers of films in the exposure box, add the mixed ECL solution to react fully, and after 1-2 minutes, remove the residual liquid, cover with a layer of film and start pressing the film. The pressed film is developed and fixed with developer and fixer reagents. Adjust the exposure conditions according to different luminescence intensities.

[0120] 5) Gel image analysis: Scan the film for archiving, organize the images and analyze the data.

[0121] 2.10 RT-PCR detection of E-cadherin, N-cadherin, and Vimintin mRNA expression in mouse liver tissue

[0122] Table 7 Primer sequences

[0123]

[0124] 2.10.1 RNA extraction from mouse liver tissue

[0125] The total RNA of the sample was extracted using Trizol reagent. The experimental steps were carried out according to the reagent instructions. The specific extraction steps were as follows: mouse liver tissue was placed in a frozen mortar and ground into powder; Trizol was added to the mortar and placed at room temperature for 5 minutes; 0.2 mL of chloroform was added and mixed thoroughly using a shaker, and then placed at room temperature for 3-5 minutes; centrifuged in a 4°C 12000rpm centrifuge for 15 minutes. After centrifugation, the liquid was divided into three layers, the upper aqueous phase was RNA, the middle aqueous phase was DNA, and the lower aqueous phase was protein and other organic substances; 300 μL of the upper aqueous phase was slowly extracted into a new centrifuge tube using a pipette (remember not to extract the liquid between the two aqueous phases); the same volume of -20°C isopropanol was added and placed on ice for 15 minutes; centrifuged in a 4°C 12000rpm centrifuge for 10 minutes, and the supernatant was slowly aspirated and discarded; 1 mL of 75% The precipitate was washed with DEPC ethanol (stored at 4°C), the gelatinous precipitate at the bottom of the wash tube was washed, oscillated to mix, and centrifuged at 4°C 12000rpm for 5 minutes; the supernatant was discarded, and the gelatinous precipitate was allowed to dry at room temperature for 5 minutes; 80 μL RNA lysis solution was added to dissolve the precipitate.

[0126] 2.10.2 RNA concentration and purity testing

[0127] The concentration of RNA was determined by ultraviolet absorption, and the concentration of RNA was determined by a wavelength of 260 nm. The absorbance ratio of the RNA solution measured at 260 nm / 280 nm ranged from 1.8 to 2.0, and the purity of the RNA extracted in this application can be estimated based on the ratio result. If the ratio is greater than 2.0, it indicates that the RNA may be degraded, and if the ratio is less than 1.8, it indicates that the extracted RNA contains impurities (such as DNA, protein, etc.).

[0128] 2.10.3 Synthesis of cDNA template

[0129] Follow the steps below according to the reverse transcription kit instructions (all experimental steps are performed on ice):

[0130] (1) Prepare cDNA removal reaction system, the formula is shown in Table 8;

[0131] (2) Incubate in a 42°C incubator for 2 min and then place on ice;

[0132] (3) Prepare the reverse transcription reaction system, the formula is shown in Table 9;

[0133] (4) adding the reverse transcription reaction system solution to the cDNA removal reaction system solution;

[0134] (5) Incubate in a 42°C incubator for 15 min and then incubate at 95°C for 3 min to obtain cDNA.

[0135] Table 8 cDNA removal reaction system

[0136]

[0137] Table 9 Reverse transcription reaction system

[0138]

[0139] 2.10.4 PCR amplification

[0140] (1) Prepare the reaction system as shown in Table 10;

[0141] (2) Reaction conditions: pre-denaturation at 95°C for 15 min; denaturation cycle 50 times, 95°C for 10 s (denaturation), 61°C for 32 s (annealing / extension);

[0142] (3) Analysis of PCR results and calculation of mRNA expression levels.

[0143] The CT values ​​of liver tissues in each group were recorded using 2 -△△CT Calculate, 2 -△△CT For 2 -(ΔCT实验组-ΔCT对照组) .

[0144] Table 10 PCR amplification reaction system

[0145]

[0146] 3 Statistical methods

[0147] The experimental data of each group were processed and analyzed using SPSS26.0 software and GraphPad Prism8.0 software, and the charts were drawn. The quantitative data were compared between groups using the mean plus or minus the standard deviation (±S). If the data between the two groups conformed to the normal distribution, the least significant difference (LSD) method was used for analysis. If it did not conform to the normal distribution, the Dunnetts T3 method was used for analysis. When P < 0.05, it was statistically significant.

[0148] Experimental Results

[0149] 4.1 General condition and weight changes of mice

[0150] In the early stage, there were no significant changes in the general conditions of the mice in each group, such as diet, body weight, and activity. With the increase in the number of days of administration, the activity of the mice in the model control group decreased significantly, the amount of food and water intake decreased significantly, they did not like to comb their hair, their hair was not shiny, and there was hair loss, and there was a large amount of ascites; the activity of the mice in the 5-fluorouracil group decreased, their activity was slightly worse, their food and water intake decreased slightly, their hair was not shiny, they occasionally lost hair, and there was a small amount of ascites; the activity of the mice in the low and medium dose groups of astragalus polysaccharides was poor, their activity decreased, their food intake was poor, their hair was dull, a small amount of hair fell off, and there was a large amount of ascites; the activity of the mice in the high dose group of astragalus polysaccharides was good, there was no significant change in the amount of food and water intake, there was no significant change in hair color, and there was a small amount of ascites. In the early stage, there was no obvious change in the weight of the mice in the model control group and the traditional Chinese medicine group. With the increase in the number of days of administration, the weight of the mice in the model control group and the traditional Chinese medicine group showed a slow upward trend, while the weight of the mice in the 5-fluorouracil group showed a significant downward trend. Figure 3 During the intervention period, one mouse died in each of the model control group, low-dose APS group, and 5-fluorouracil group.

[0151] 4.2 Effect of Astragalus Polysaccharide on Mouse Model of Colorectal Cancer Liver Metastasis

[0152] like Figure 4 As shown, Figure 4 This is a gross observation of the liver metastasis lesions in mice. Through observation of the mouse livers, it can be found that the model control group mice had more slightly larger gray-white liver metastasis nodules on the liver surface, and the liver structure was almost invisible; the low-dose and medium-dose mice of Astragalus polysaccharide also had more gray-white nodules on the liver surface, but the nodules were slightly smaller than those in the model control group; the liver surface of the high-dose Astragalus polysaccharide group and 5-fluorouracil mice was smooth and regular, and the surface structure was intact.

[0153] 4.3 Imaging results of metastatic lesions detected by in vivo imaging

[0154] like Figure 5 As shown, Figure 5 (a) is the fluorescence imaging result of mice 7 days after modeling. Figure 5 (b) is the fluorescence imaging result of mice 21 days after drug intervention. Figure 5 (c) is the fluorescence imaging ROI value 7 days after mouse modeling. Figure 5(d) is the fluorescence imaging ROI value of mice after 21 days of drug administration. The results of in vivo imaging of small animals showed that after 1 week of modeling, the liver tissue area of ​​mice showed fluorescence imaging, indicating that the tumor had liver metastasis, and there was no statistically significant difference in ROI value (fluorescence area) among the groups (P>0.05). After 21 days of drug intervention, the fluorescence imaging ROI value of mice in each experimental group was significantly lower than that in the model control group, among which the ROI value of mice in the 5-fluorouracil group was the lowest (P<0.05). In the Chinese medicine group, with the increase of drug concentration, the fluorescence imaging ROI value gradually decreased, among which the ROI value of mice in the high-dose astragalus polysaccharide group was the lowest (P<0.05). Figure 5 Compared with the model control group, a P<0.05; compared with the low-dose group of Astragalus polysaccharide, b P<0.05; compared with the medium-dose group of Astragalus polysaccharide c P<0.05; compared with the 5-fluorouracil group, d P<0.05. A: model control group, B: 5-fluorouracil group, C: low-dose astragalus polysaccharide group, D: medium-dose astragalus polysaccharide group, E: high-dose astragalus polysaccharide group.

[0155] 4.4 Pathological staining of mouse liver tissue

[0156] like Figure 6 As shown, Figure 6 Mouse liver tissue pathological staining (200x). The tumor cells in the model control group were closely arranged, with obvious heteromorphism, and obvious megakaryocytes and heteromorphic nuclei. The tumor cells in the low-dose APS group were slightly sparser than those in the control group, but the cells still had obvious heteromorphism. The tumor cells in the medium-dose APS group were relatively sparsely arranged, with lighter nuclear staining and fewer nuclear divisions. The liver structures of the mice in the high-dose APS and 5-fluorouracil groups were relatively intact, with neatly arranged liver cells and occasional atypical cells.

[0157] 4.5 Expression of TGF-β / Smad signaling pathway proteins and EMT-related proteins in mouse liver metastases

[0158] In order to clarify how Astragalus polysaccharide regulates the effect of TGF-β / smad signaling pathway proteins on EMT, this application analyzed the expression of TGF-β1, the ratios of p-Smad2 / Smad2, p-Smad3 / Smad3, and the expression of E-cadherin, N-cadherin, and Vimentin proteins in mouse liver metastases; Figure 7 As shown, Figure 7 (a) shows the protein bands of TGF-β1, Smad2, Smad3, p-Smad2, p-Smad3, E-cadherin, N-cadherin and Vimentin in the liver tissues of mice in each group. Figure 7 (b) is the expression of TGF-β / smad signaling pathway and EMT-related proteins in mouse liver tissue. The results showed that compared with the model control group, all experimental groups were able to inhibit the expression of TGF-β1 (P < 0.05), and the high-concentration astragalus polysaccharide group had the strongest inhibitory ability among the Chinese medicine groups (P < 0.05); in addition, compared with the model control group, all experimental groups were able to downregulate the ratios of p-Smad2 / Smad2 and p-Smad3 / Smad3 (P < 0.05), and the high-concentration astragalus polysaccharide group had the lowest ratios of p-Smad2 / Smad2 and p-Smad3 / Smad3 in the liver metastasis of mice in the Chinese medicine group (P < 0.05); all experimental groups were able to increase E-cadhe rin protein expression, down-regulated the expression of N-cadherin and Vimentin proteins (P < 0.05); among them, the 5-fluorouracil group had the highest expression of E-cadherin protein in all groups, and the lowest expression of N-cadherin and Vimentin proteins (P < 0.05); in addition, in the Chinese medicine group, with the increase of drug concentration, the expression of E-cadherin gradually increased (P < 0.05), and the expression of N-cadherin and Vimentin gradually decreased (P < 0.05); therefore, the present application concluded that astragalus polysaccharide may inhibit the occurrence of EMT by regulating the TGF-β / smad signaling pathway, thereby inhibiting the liver metastasis of colorectal cancer in mice. Figure 7 Compared with the model group, a P<0.05; compared with the low-dose group of Astragalus polysaccharide, b P<0.05; compared with the medium-dose group of Astragalus polysaccharide c P<0.05; compared with the 5-fluorouracil group, d P<0.05. A: model control group, B: 5-fluorouracil group, C: low-dose astragalus polysaccharide group, D: medium-dose astragalus polysaccharide group, E: high-dose astragalus polysaccharide group.

[0159] 4.6 Expression of inflammatory factors TNF-α, IL-1β, and IL-6 in mouse serum

[0160] The expression levels of mouse inflammatory factors TNF-α, IL-1β, and IL-6 are shown in Table 11. Figure 8 As shown in the results, compared with the model control group, the levels of serum TNF-α, IL-1β, and IL-6 inflammatory factors in the mice in each experimental group were significantly reduced (P < 0.05), among which the serum inflammatory factor level of the mice in the high-dose astragalus polysaccharide group was the lowest (P < 0.05). Compared with the 5-fluorouracil group, there was no statistically significant difference in the expression of serum TNF-α in the high-dose astragalus polysaccharide group (P > 0.05), while the levels of IL-1β and IL-6 inflammatory factors in the high-dose group were lower than those in the 5-fluorouracil group (P < 0.05). Figure 8 Compared with the model group, a P<0.05; compared with the low-dose group of Astragalus polysaccharide, b P<0.05; compared with the medium-dose group of Astragalus polysaccharide c P<0.05; compared with the 5-fluorouracil group, d P<0.05. A: model control group, B: 5-fluorouracil group, C: low-dose astragalus polysaccharide group, D: medium-dose astragalus polysaccharide group, E: high-dose astragalus polysaccharide group.

[0161] Table 11 Expression levels of mouse inflammatory factors TNF-α, IL-1β, and IL-6 (pg / mL, n=3)

[0162]

[0163]

[0164] 4.7 Expression of E-Cadherin, N-Cadherin, and Vimentin mRNA in Mouse Liver Metastases

[0165] The expression levels of N-Cadherin, N-cadherin, and Vimentin mRNA were obtained by detecting mouse liver metastasis by fluorescent real-time quantitative PCR. E-Cadherin is an epithelial marker in epithelial-mesenchymal transition (EMT), and N-Cadherin and Vimentin are mesenchymal markers, as shown in Table 12, Fig. 9 As shown. Through the analysis of the experimental results, the present application can conclude that each experimental group can upregulate the expression of E-cadherin mRNA, and can downregulate the expression of N-cadherin and Vimentin mRNA (P < 0.05). The expression level of E-cadherin mRNA in the traditional Chinese medicine group gradually increases with the increase of the drug concentration (P < 0.05), and the expression level of E-cadherin mRNA in the traditional Chinese medicine group is higher than that in the positive control group (P < 0.05). The expression levels of N-cadherin and Vimentin mRNA in the traditional Chinese medicine group decrease with the increase of the drug concentration (P < 0.05). There is no statistically significant difference between the high-dose astragalus polysaccharide group and the positive control group (P > 0.05). Compared with the model group, a P<0.05; compared with the low-dose group of Astragalus polysaccharide, b P<0.05; compared with the medium-dose group of Astragalus polysaccharide c P<0.05; compared with the 5-fluorouracil group, dP<0.05. A: model control group, B: 5-fluorouracil group, C: low-dose astragalus polysaccharide group, D: medium-dose astragalus polysaccharide group, E: high-dose astragalus polysaccharide. It can be seen that astragalus polysaccharide can inhibit the occurrence of tumor epithelial-mesenchymal transition (EMT).

[0166] Table 12 Expression of E-Cadherin, N-Cadherin and Vimentin mRNA in mouse liver metastases ( n=3)

[0167]

[0168] It should be noted that, in this article, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device that includes a series of elements includes not only those elements, but also includes other elements that are not explicitly listed, or also includes elements inherent to such process, method, article or device; although the embodiments of the present application have been shown and described, it can be understood by those of ordinary skill in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and spirit of the present application, and the scope of the present application is defined by the appended claims and their equivalents.

Claims

1. A method for preparing astragalus polysaccharide composite nanoparticles for anti-colorectal cancer, characterized in that: The steps include: S1. Under stirring conditions, liquid paraffin and Span 80 are mixed evenly, and a polyethyleneimine aqueous solution is added dropwise within 20-40 minutes, and the reaction is completed for 0.5-1.5 hours. Then, a glutaraldehyde aqueous solution is added dropwise within 1-3 hours, and the temperature is raised to 40-60° C., and the reaction is continued for 8-12 hours. The mixture is cooled to room temperature, and the mixture is centrifuged, washed, and dried to obtain polyethyleneimine nanoparticles; S2. Dispersing the polyethyleneimine nanoparticles obtained in step S1 in ethanol under stirring, adding epichlorohydrin dropwise, heating to 55-65° C., reacting for 3-7 hours, then sequentially adding carboxymethyl chitosan aqueous solution and N,N-diisopropylethylamine, then heating to 75-90° C., continuing to react for 7-10 hours, cooling to room temperature, centrifuging, washing, and drying to obtain modified polyethyleneimine nanoparticles; S3, under stirring conditions, dispersing astragalus polysaccharide in a phosphate buffer solution, adding the modified polyethyleneimine nanoparticles obtained in step S2, reacting at room temperature for 20-30 hours, centrifuging, washing, and drying to obtain modified polyethyleneimine nanoparticles loaded with astragalus polysaccharide; S4. Under stirring conditions, the modified polyethyleneimine nanoparticles loaded with astragalus polysaccharide are dispersed in a phosphate buffer solution, and enteric materials and emulsifiers are added in sequence. The mixture is stirred at room temperature for 20-30 hours, and the astragalus polysaccharide composite nanoparticles are obtained after centrifugation, washing and drying.

2. The method for preparing astragalus polysaccharide composite nanoparticles for treating colorectal cancer according to claim 1, characterized in that: In step S1, the volume ratio of the liquid paraffin, Span 80, polyethyleneimine aqueous solution and glutaraldehyde aqueous solution is 10-14:10-15:4:3-5.

3. The method for preparing astragalus polysaccharide composite nanoparticles for treating colorectal cancer according to claim 2, characterized in that: The mass fraction of polyethyleneimine in the polyethyleneimine aqueous solution is 10-30%, and the mass fraction of glutaraldehyde in the glutaraldehyde aqueous solution is 3-5%.

4. The method for preparing astragalus polysaccharide composite nano-microspheres for treating colorectal cancer according to claim 1, characterized in that: The mass ratio of the polyethyleneimine nanospheres, epichlorohydrin, carboxymethyl chitosan aqueous solution, and N,N-diisopropylethylamine in step S2 is 1:0.15-0.25:10-15:0.25-0.

35.

5. The method for preparing astragalus polysaccharide composite nanoparticles for treating colorectal cancer according to claim 4, characterized in that: The amount of polyethyleneimine nanospheres added to the ethanol is 60-90 mg / mL, the mass fraction of carboxymethyl chitosan in the carboxymethyl chitosan aqueous solution is 3-5%, and the dripping speed of epichlorohydrin is 4-6 μL / s.

6. The method for preparing astragalus polysaccharide composite nanoparticles for treating colorectal cancer according to claim 1, characterized in that: In step S3, the amount of astragalus polysaccharide added to the phosphate buffer solution is 0.4-0.6 mg / mL, and the mass ratio of astragalus polysaccharide to modified polyethyleneimine nanospheres is 1:2-4.

7. The method for preparing astragalus polysaccharide composite nanoparticles for treating colorectal cancer according to claim 1, characterized in that: In step S4, the mass ratio of the modified polyethyleneimine nanoparticles loaded with astragalus polysaccharide, the enteric material, and the emulsifier is 10:15-25:0.7-0.8, and the amount of the modified polyethyleneimine nanoparticles loaded with astragalus polysaccharide added to the phosphate buffer solution is 50-70 mg / mL.

8. The method for preparing astragalus polysaccharide composite nano-microspheres for treating colorectal cancer according to claim 7, characterized in that: The enteric material is composed of acrylic resin II and acrylic resin III in a mass ratio of 1:2-3; and the emulsifier is polyvinyl alcohol.

9. An astragalus polysaccharide composite nanoparticle for anti-colorectal cancer, characterized in that: The method is prepared by any one of claims 1 to 8.

Citation Information

Patent Citations

  • Pericarpium citri reticulatae polysaccharide-PEI (polyetherimide) composite nanoparticles as well as preparation method and application thereof

    CN117643626A

  • Marker for evaluating curative effect of colorectal cancer patient after astragalus polysaccharide intervention treatment and application of marker

    CN118207331A